Skip to main content

Tardive Dyskinesia

Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020. 
A retrospective study involving 7985 veterans found which medication or medication class was associated with the highest risk of tardive dyskinesia?
Despite the impact the COVID-19 pandemic has had on psychiatry practice, a proactive, routine, and systematic assessment for tardive dyskinesia in patients taking antipsychotics is a mandate for all clinicians, Rakesh Jain, MD, MPH, said at Psych…
Back to Top